B.Pharm 1975 College of Pharmaceutical Sciences Medical College, Trivandrum, India. M.Pharm 1978 Manipal College of Pharmaceutical Sciences,Manipal, India Ph.D 1996 Manipal College of Pharmaceutical Sciences, Manipal, India PGDCR 2005 Catalyst Clinical Services Pvt.Ltd.New Delhi.(India) Clinical research associate- Navaratna pharmaceuticals 1979-1980 Lecturer - Manipal university 1980 - 1982 Assistant professor – Manipal university -1982 - 1984 Reader – Manipal university 1984 -1995 Associate professor Manipal university 1995 -1998 Professor & head of department , Manipal university 2003-2008 Director -Contract Research Organization -Manipal AcuNova Chairperson & Associate Dean - RAKCOPS She is a Life member of Indian Pharmaceutical Association, Indian Pharmacological Scociety and Association of Pharmaceutical teachers of India Also she is an Executive Member- Pharm D program Executive Council Member- Manipal Acunova(CRO)

Clinical Pharmacy & Therapecutics, Pharmacology

Dr. Bikash Medhi is Professor & Additional Medical Superintendent (AMS) in PGIMER, Department of Pharmacology. His area of expertise is Experimental Pharmacology, Clinical Research, Regulatory Pharmacology, Development of nano-formulations, Pharmacogenetics, Pharmacogenomics and Stem cells etc. He has more than 20 years of teaching and research experience and has owned more than 50 prestigious national and international awards namely, Dr. D N Prasad memorial award with Gold medal 2009 from Indian Council of Medical Research (ICMR), New Delhi, V K Bhargava Award with a Gold medal from National Academy of Medical Sciences 2013, Col. R N Chopra Oration 2014 by Indian Pharmacology Society(IPS), NN Dutta Award 2016 by Indian Pharmacology Society(IPS), Dr. B N. Ghosh Oration at 43 rd Annual Conference of IPS and International Conference on “Pharmacology & Translational Research” He is in core panel of expert for Task Force in IND application, GLP Inspector, GCP inspector, to frame guidelines for submission of dossiers or proposals for regulation of biotech products (r-D~A product), Govt. of India, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi. He is in Editorial Board member in several World Journal of Gastroenterology (2010-2012), Journal of Neuroscience and Behavioral Health. He has authored five books and 60 chapters and published more than 200 articles in National & International journals. Further, he was selected as a member of various central government committees (GOI) and central government funding agencies: in the IND committee, FDC Committee, Compensation Committee, Sub-committee of Drug Regulation, Schedule Y amendment Committee, Central Working Group Committee for Pharmacovigilance(PvPI), Signal Preview Committee–, Member of Biologic Task Force DGCI-DBT committee, Member of GCP inspection team DCGI, Core Training Panel Committee Pharmacovigilance (PvPI), National Formulary Committee(NFI)–IPC, Chairman selection Committee for TA(IPC), Special Invitee for national Advisory board of Haemovigilance programme, member of the committee for evaluation of Spurious Drugs, antimicrobial evaluation committee(ICMR). Basic Medical Sciences Project evaluation Committee (ICMR), ?-HCG Vaccine Committee(ICMR), Member for procurement of Instruments for ICMR institute, Core member for Committee ICMR-NIREH Bhopal, member of ICMR funding to CDRI, Special Invitee - TB Task Force, DBT Task Force member, the Expert member for anti-doping (NADA) and member of Expert group NADA, National Board Examination (NBE), Senate and selection committee member for NIPER, Member of Board of studies of Punjab University, Chandigarh, Working as GLP inspector for GLP monitoring authority (DST, New Delhi), member of Technical committee Department of Health Research(DHR), Ministry of health.

Experimental Pharmacology, Clinical Research, Regulatory Pharmacology, Development of nano-formulations, Pharmacogenetics, Pharmacogenomics and Stem cells

Dr Hussain Nasser Al Rahma, the President of the 7th Conference of Emirates Intensive Care Society, President of the International Pan Arab Critical Care Medicine Society , Chairman of the Emirates Intensive Care Society and head of ICU, Dubai Hospital.

Critical Care Medicine, Trauma, Mortality rates

He is the president of Biotechnological Drug Society and currently working as a professor of Gazi University Medical School Department of Pharmacology. He also serves as a consultant in pharmacoeconomics, clinical trials, pharmacovigilance, drug interactions, drug research and development

pharmacoeconomics, clinical trials, pharmacovigilance, drug interactions, drug research

Dr. Yukio Yoneda is a Professor Emeritus in Kanazawa University, where he worked as a Chairman Professor of Pharmacology from 1999 to 2015. He graduated from Osaka University, Faculty of Pharmaceutical Sciences in 1972, followed by appointments in Kyoto Prefectural University of Medicine, City of Hope Research Institute, CA, USA and Setsunan University. He is serving as an Associate Editor in several international journals such as Neurochemistry International, Neurochemical Research and Journal of Neuroscience Research, in addition to acting on the Editorial Board in other international scientific journals. His research interests have been lying on pharmacological profiling of amino acid signaling in neuronal and non-neuronal cells using molecular biological techniques. As a return of laboratory experimental results to the community, he is now attempting to develop several dietary supplements beneficial for the prophylaxis of different diseases besides the bench work with colleagues in domestic and foreign universities.

Molecular pharmacology of amino acid signaling in neuronal and non-neuronal cells

Dr. Ramadan M. Elkalmi is currently working as senior lecturer of clinical pharmacy and pharmacy practice at Universiti Teknologi MARA (UiTM), Malaysia. He had received his PhD in pharmacy practice and health system research at university Sains Malaysia (USM), Penang, Malaysia. He had received MPharm (Master) degree at university Sains Malaysia (USM), Penang, Malaysia in the year of 2003 d completed his BSc in pharmaceutical sciences at Tripoli uncivility (1993/1994). He served as a lecturer and head of pharmacology department in faculty of medicine at university of Sabha, Libya from 2005 to 2011. His major research interests are Pharmacovigilance, pharmacoepidemiology and social &behavioral aspects of pharmacy and health, quantitative and qualitative aspects of medication usage especially adherence and prescribing and non-prescription medication, evaluation and analysis of pharmaceutical policies and pharmacy education. Dr. Ramadan also honored with award of “Sanggar Sanjung 2010” award from USM for excellence achievement (publication category). He has published about 50 articles as author and co-coauthor in many peer reviewed international journals. In addition, Dr. Ramadan serves as editorial board member and as reviewer form many reputable international journals. Beside his involvement in teaching under graduate pharmacy students in different field of clinical pharmacy and pharmacy practice, he also involved in supervising undergraduate/postgraduate pharmacy students.

Quantitative and qualitative aspects of medication usage research. Pharmacoepidemiology and pharmacovigilance Pharmacy education

Yoshiko Yamaguchi has received her Ph. D in Kyushu University, Japan. Currently, she is working as research associate in Home Care Nursing, Faculty of Nursing, Kwassui Women’s University, Japan. She has successfully completed her responsibilities as reviewer for 11 papers from year of 2016 to 2017. She is serving as an editor of International Journal of Nursing & Clinical Practices and Journal of Comprehensive Nursing Research and Care. And she is honorary president of the scholarly association IAPHLSR: International Association for Promotion of Healthcare and Life-Science Research. She has been awarded as a best presentation of 7th International Conference on Healthcare, Nursing and Disease Management, 2016, Singapore. (Oral presentation), and as a best paper of Journal of Japan Academy of Nursing Administration and Policies, (Research article), 2013

Nursing Research, Healthcare and Life science Research

Dr. Silay is serving as the Chairman of İstanbul Consulting Group and Director of Avcılar Hospital R&D Center in Europe, providing clinical trial administration, market access, medical writing, patient recruitment, retention, regulatory and medical affairs support, drug repositioning for hospitals, academic institutions and pharmaceutical companies from preclinical to post marketing stages for several years. Dr. Silay is also providing comprehensive and strategic consulting services for the approval of Drugs and Medical Devices and attended several meetings with FDA, EMA, Health Canada and Turkish Health authorities and social security institute.Dr. Silay in USA, most recently worked as the Vice President, Medical Affairs, and head of Medical Affairs Neurology in the US headquarters Basking Ridge, New Jersey reporting to the President and CEO of Ipsen North America where he was key in building a Neurology Franchise by hiring many employees. Dr. Silay is a senior consultant, project manager, executive physician scientist, certified clinical research professional in the healthcare ( pharmaceutical, medical device, hospital chains) industry with an Executive MBA degree from the Olin Business School at Washington University in St. Louis which is ranked #2 in United States of America by Wall Street Journal in 2010. Dr. Silay is a member of American Academy of Neurology, chief editor of Journal of Developing Drugs, an editorial board member of Expert opinion on Emerging Drugs, a current ad-hoc reviewer at the NIH ( National Institute of Health) and NINDS, past speaker at DIA ( Drug Information Association) and member of DIA SIAC’s for Good Clinical Practice/Quality Assurance Special Interest Activity Community (GCP/QA SIAC), Clinical Trial Registry/Results Disclosure Working Group (CTR/RD Working Group), Natural Health Products. , MDS (Movement Disorder Society) , current secretary general of HEPA (Health Economics& Policy Association), charter and previous president of AMSA (American Medical Student Association) Turkey, previous president of SOCRA (Society of Clinical Research Associates) in New Jersey, board of directors member at the SoPE and founder of SoPE(Society of Physician Entrepreneurs) Turkey chapter. Dr. Silay is a recognized senior consultant executive in the public health, PPP, health economics and pharmaceutical industry with a track record of conducting successful, carefully designed outcomes trials as well as randomized double blind placebo controlled clinical trials in CNS (Central Nervous System) therapeutic area such as Parkinson’s, MS (Multiple Sclerosis), Stroke, head trauma, Fibromyalgia, Tourette syndrome, Alzheimer’s disease as well as Pulmonary Critical Care/ Lung transplant, Cardivascular (Cardiac stent, MI, Ambulatory Blood pressure monitoring trials) and Oncology therapeutic areas. Dr. Silay, a dual citizen of U.S.A. and Turkey was born in Turkey and educated in Turkey, Germany and U.S.A. He completed his medical School at The University of Ankara in Turkey and his internship at Baylor College of Medicine and University of Texas in Houston, Texas. He attended a Physician Scientist Training Program at The MD Anderson Cancer Center of University of Texas. Dr. Silay worked on projects with several Pharmaceutical companies such as Astellas, Chiron, Fugisawa, Nabi Biopharmaceutical, Forest Pharmaceuticals, KV Pharmaceuticals, Medtronics, Deep Breeze, Teva, Ipsen as well as governmental organizations such as NIH, Chest foundation, American heart association grants, FDA, Turkish minister of Health and the World Bank As a prolific scientific writer he published extensively with more than 15 peer reviewed article and more than 100 platform and abstract presentation at the academic and industry level in national and international meetings. Dr. Silay is currently serving as the Chairman of the Istanbul Consulting Group (ICG) . He provides guidance and support to Turkish Ministry of health through World bank project. As the former General Manager of the largest distributor of Siemens healthcare company with ~220 employees, he played key role in developing mobile Breast cancer screening program for Turkish and Syrian refugees in Turkey. As a BioPharma CEO, Carveout, Turnaround Specialist he is known as, Entrepreneur Doctor & "International Healthcare Executive (Pharmaceutical, Hospital Chain, Diagnostic & Medical Device)", Management Consultant, "Business, Strategy, Marketing Savvy Physician. He has Proven ability to build high performing teams and productive organizations, turn around brands, and build revenue in diverse markets. As the former director, Market Access & Health Policy for AIFD( Research Based Pharmaceutical Companies) which the 40 members represent all major global pharmaceutical companies, 650 billion dollars of 1 billion dollar Global Pharmaceutical market. He represented pharmaceutical companies and was in discussion with all ministerial levels, including ministry of health, finance, labor, development and science& technology in Turkey.

Neurology, Pulmonary Critical Care, Rheumatology, Oncology and related therapeutic areas within academics and industry. regulatory processes, identifying and addressing risk management issues throughout lifecycle, presentation development to large payers, safety monitoring, designing and conducting clinical trials.